Your browser doesn't support javascript.
Humoral response to spike S1 and S2 and nucleocapsid proteins on microarray after SARS-CoV-2 infection.
Portilho, Amanda I; Silva, Valéria O; Ahagon, Cintia M; Matsuda, Elaine M; de Oliveira, Elaine L; da Silveira, Edilene P R; de Souza Lima, Ana K; Lindoso, José A L; de Campos, Ivana B; Hong, Marisa A; De Gaspari, Elizabeth; de Macedo Brígido, Luís F.
  • Portilho AI; Institute Adolfo Lutz, Center of Immunology, São Paulo, Sao Paulo, Brazil.
  • Silva VO; Institute Adolfo Lutz, Center of Virology, São Paulo, Sao Paulo, Brazil.
  • Ahagon CM; Institute Adolfo Lutz, Center of Virology, São Paulo, Sao Paulo, Brazil.
  • Matsuda EM; Department of Santo André Health, Infectious Diseases Outpatient Clinic, Santo André, Sao Paulo, Brazil.
  • de Oliveira EL; Institute Adolfo Lutz, Center of Immunology, São Paulo, Sao Paulo, Brazil.
  • da Silveira EPR; Institute Adolfo Lutz, Center of Immunology, São Paulo, Sao Paulo, Brazil.
  • de Souza Lima AK; Institute of Infectology Emilio Ribas, São Paulo, Sao Paulo, Brazil.
  • Lindoso JAL; Institute of Infectology Emilio Ribas, São Paulo, Sao Paulo, Brazil.
  • de Campos IB; Institute Adolfo Lutz, Santo André Regional Center, Santo André, São Paulo, Brazil.
  • Hong MA; Institute Adolfo Lutz, Center of Immunology, São Paulo, Sao Paulo, Brazil.
  • De Gaspari E; Institute Adolfo Lutz, Center of Immunology, São Paulo, Sao Paulo, Brazil.
  • de Macedo Brígido LF; Institute Adolfo Lutz, Center of Virology, São Paulo, Sao Paulo, Brazil.
J Med Virol ; 94(1): 178-185, 2022 01.
Article in English | MEDLINE | ID: covidwho-1544336
ABSTRACT
Many aspects of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as its role in protection after natural infection, are still unclear. We evaluated IgA and IgG response to spike subunits 1 and 2 (S1 and S2) and Nucleocapsid proteins of SARS-COV-2 in serum samples of 109 volunteers with viral RNA detected or seroconversion with different clinical evolution (asymptomatic, mild, moderate, and severe coronavirus disease 2019), using the ViraChip® Test Kit. We observed that the quantification of antibodies to all antigens had a positive correlation to disease severity, which was strongly associated with the presence of comorbidities. Seroreversion was not uncommon even during the short (median of 77 days) observation, occurring in 15% of mild-asymptomatic cases at a median of 55 days for IgG and 46 days for IgA. The time to reach the maximal antibody response did not differ significantly among recovered and deceased volunteers. Our study illustrated the dynamic of anti-S1, anti-N, and anti-S2 IgA and IgG antibodies, and suggests that high production of IgG and IgA does not guarantee protection to disease severity and that functional responses that have been studied by other groups, such as antibody avidity, need further attention.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / Coronavirus Nucleocapsid Proteins / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: J Med Virol Year: 2022 Document Type: Article Affiliation country: Jmv.27290

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / Coronavirus Nucleocapsid Proteins / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: J Med Virol Year: 2022 Document Type: Article Affiliation country: Jmv.27290